Journal of Pain and Symptom Management
Volume 39, Issue 3 , Pages 548-554, March 2010

Lack of Benefit From Paracetamol (Acetaminophen) for Palliative Cancer Patients Requiring High-Dose Strong Opioids: A Randomized, Double-Blind, Placebo-Controlled, Crossover Trial

  • Fiona J. Israel, RN, MCouns

      Affiliations

    • Brisbane South Palliative Care Collaborative, Brisbane, Queensland, Australia
    • Queensland Health, Brisbane, Queensland, Australia
    • Griffith University School of Medicine, Brisbane, Queensland, Australia
    • Mt. Olivet Palliative Services, Brisbane, Queensland, Australia
    • Corresponding Author InformationAddress correspondence to: Fiona J. Israel, RN, MCouns, Brisbane South Palliative Care Collaborative, P.O. Box 4069, Eight Mile Plains, Queensland 4113, Australia.
  • ,
  • Greg Parker, MBBCH

      Affiliations

    • Queensland Health, Brisbane, Queensland, Australia
    • Brisbane South Palliative Care Services, Brisbane, Queensland, Australia
  • ,
  • Margaret Charles, BA, PhD

      Affiliations

    • School of Psychology, University of Sydney, Sydney, New South Wales, Australia
  • ,
  • Liz Reymond, MBBS(Hons), PhD, FRACGP, FAChPM

      Affiliations

    • Brisbane South Palliative Care Collaborative, Brisbane, Queensland, Australia
    • Queensland Health, Brisbane, Queensland, Australia
    • Griffith University School of Medicine, Brisbane, Queensland, Australia
    • Mt. Olivet Palliative Services, Brisbane, Queensland, Australia
    • Brisbane South Palliative Care Services, Brisbane, Queensland, Australia

Accepted 24 July 2009. published online 18 January 2010.

Abstract 

Context

The adjunctive use of paracetamol (acetaminophen) with strong opioids has become entrenched practice in palliative care pain management, despite little evidence to support its use.

Objective

The study aim was to investigate potential analgesic benefits of 4g of paracetamol daily for palliative cancer patients requiring high-dose opioids.

Methods

Thirty-one patients, using at least 200mg of oral morphine equivalent daily, were recruited to a prospective, double-blinded, randomized, crossover trial. Patients received usual medications plus 4g of paracetamol or placebo for five days each in random order. Primary outcome, effect on pain, was assessed using daily diaries, including a numerical rating scale (NRS) from zero (no pain) to 10 (unbearable) and recording numbers of breakthrough analgesics. Secondary outcomes—nausea, vomiting, cognitive impairment, constipation, and overall well-being—were assessed using the NRS. Data from the last four days of each treatment were analyzed. Patients also indicated in which part of the study their pain was better controlled.

Results

Twenty-two patients, requiring a median dose of 255mg of oral morphine equivalent daily, completed the trial. There were no significant order or treatment-by-order interaction effects for any variable; paired t-tests were conducted to investigate change in mean levels on outcome variables with placebo vs. paracetamol. For none of the variables was there a statistically significant difference when assessed with placebo compared with paracetamol. No change approached clinically significant levels, with a mean difference in rated pain of 0.16, and mean difference of 0.42 for a number of breakthrough medications. Fifteen patients were undecided whether paracetamol improved pain.

Conclusions

These data do not support the common practice of adding regular paracetamol daily as an adjunct to high-dose opioids for pain control in cancer patients receiving palliative care.

Key Words: Pain, paracetamol, acetaminophen, high-dose opioids, strong opioids, cancer, palliative care

 

 This research was supported by the Brisbane South Palliative Care Collaborative, a joint partnership between Queensland Health, Metro South Health Service District, Griffith University School of Medicine, and Mt. Olivet Community Services.

PII: S0885-3924(09)01138-5

doi:10.1016/j.jpainsymman.2009.07.008

Journal of Pain and Symptom Management
Volume 39, Issue 3 , Pages 548-554, March 2010